Asset Details
Do you wish to reserve the book?
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
Do you wish to request the book?
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
2010
Overview
Despite highly active antiretroviral therapy, active replication persists and drives immune activation in some individuals with HIV. This activation is higher if therapy is intensified by additional antiretroviral drugs (
pages 373–374
).
Highly active antiretroviral therapy (HAART) results in potent and durable suppression of HIV-1 viremia. However, HIV-1 replication resumes if therapy is interrupted
1
,
2
. Although it is generally believed that active replication has been halted in individuals on HAART, immune activation and inflammation continue at abnormal levels
3
, suggesting continued, low-level viral replication. To assess whether active replication might be driving immune activation in HAART, we examined the impact of treatment intensification with the integrase inhibitor raltegravir on viral complementary DNA and immune activation parameters. In the presence of raltegravir, linear HIV-1 cDNA is prevented from integrating into chromatin and is subsequently converted to episomal cDNAs
4
,
5
. Raltegravir intensification of a three-drug suppressive HAART regimen resulted in a specific and transient increase in episomal DNAs in a large percentage of HAART-suppressed subjects. Furthermore, in subjects with these episomal DNAs, immune activation was higher at baseline and was subsequently normalized after raltegravir intensification. These results suggest that, despite suppressive HAART, active replication persists in some infected individuals and drives immune activation. The ability of raltegravir intensification to perturb the reservoir that supports active replication has implications for therapeutic strategies aimed at achieving viral eradication.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Antiretroviral Therapy, Highly Active
/ Biomedical and Life Sciences
/ DNA
/ DNA, Complementary - genetics
/ Highly active antiretroviral therapy
/ HIV
/ HIV Infections - drug therapy
/ HIV Integrase Inhibitors - pharmacology
/ HIV Integrase Inhibitors - therapeutic use
/ HIV Long Terminal Repeat - drug effects
/ HIV Long Terminal Repeat - genetics
/ Human immunodeficiency virus
/ Human immunodeficiency virus 1
/ Humans
/ letter
/ Pyrrolidinones - pharmacology
/ Pyrrolidinones - therapeutic use
/ Virus Integration - drug effects
